Updates are available Correction dated 2022-08-06
Click to view Correction: https://doi.org/10.1007/s12094-022-02905-9
-
Authors
Castañeda, Santos
Casas, Ana
González-del-Alba, Aránzazu
Martínez-Díaz-Guerra, Guillermo
Nogués, Xavier
Ojeda Thies, Cristina
Torregrosa Suau, Óscar
Rodríguez-Lescure, Álvaro http://orcid.org/0000-0002-6823-5290
-
Funding
Funding for this research was provided by:
Sociedad Española de Oncología Médica
- License Information
-
More Information
Article History
Received: 9 February 2022
Accepted: 5 June 2022
First Online: 2 July 2022
Change Date: 6 August 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s12094-022-02905-9
Declarations
:
: Santos Castañeda has received personal fees from Amgen, Gebro Pharma, Gedeon-Richter Spain, Grünenthal, Lilly, MSD, Pfizer, Roche, Sanofi, Stada, SOBI and UCB, and he is assistant professor of the UAM-Roche EPID-Future chair, Universidad Autónoma de Madrid (UAM), Madrid, Spain. Ana Casas has received consultant or speaker’s fees from Novartis, Roche, Astra Zeneca and Pierre Fabre. Aránzazu González-del-Alba has received research funding from Astellas, travel grants from Astellas, Jansen, Sanofi, BMS, Roche, Pfizer, MSD and Ipsen and honoraria for speaking engagements, membership of advisory boards and continuing medical education from Janssen, Astellas, Sanofi, Bayer, Roche, Ipsen, BMS, MSD, Pfizer, Eusa Pharma, Eisai and Astra Zeneca. Guillermo Martínez-Díaz-Guerra has received research funding from Lilly and Amgen; travel grants from Lilly, UCB, and Amgen; speaker’s fees from Lilly, Amgen, Kyowa Kirin, Italfármaco, and Gebro Pharma; and honoraria for membership of advisory boards and continuing medical education from Lilly, UCB, Amgen, Kyowa Kirin, Takeda, and Alexion. Xavier Nogués has received consultant or speaker’s fees from Amgen, Lilly, Faes Farma and UCB Pharma. Cristina Ojeda Thies has recieved honoraria for presentations and continuing medical education from AMGEN, UCB Pharma, Grünenthal and MBA Surgical Empowerment. Óscar Torregrosa Suau declares no conflicts of interest. Álvaro Rodríguez-Lescure has received consultant or advisor fees from Roche, Pfizer, Novartis, Lilly, MSD, AstraZeneca, and Daiichi-Sankyo, and research funding for his institution from Roche, Novartis, Pfizer, Lilly, AstraZeneca, Amgen, MSD, BMS, Zymeworks, and GEICAM; he has also received speaker’s fees from Roche, Pfizer, Novartis, Lilly, AstraZeneca, MSD, Merck, Pierre-Fabré, and Ipsen.
